1. Systematically define high-impact, high-demand clinical areas How – Delphi?? 2. Build personalized trial implementation platforms & resources This is being done currently 3. Form multi-stakeholder collaboratives to inform best practices and policies I think we should invite some patients/consumers to join our network One for N-of-1s and one for SCEDs? 4. Construct open deep phenotype data bank We need to decide whether to do a rare disease or CF or a common problem like insomnia. Maybe use results from high-impact, high-demand clinical areas exploration to define the area we address. What are your thoughts on how we can address these strategies suggested by Karina Davidson?

"N-of-1 study" and "SCED" can describe both individual and aggregated studies. This can be confusing. What about meta N-of-1 studies for aggregated N-of-1 studies and meta SCEDs for meta-analysis of SCEDs? Or do you have an alternative suggestion/s? Let us know what you think.....

We are keen to find out what the barriers are stopping clinicians from conducting SCEDs or N-of-1 studies with their own patients/clients.